Regenxbio Inc. (RGNX) Trading Down 4%
Shares of Regenxbio Inc. (NASDAQ:RGNX) were down 4% on Tuesday . The company traded as low as $13.01 and last traded at $13.03, with a volume of 58,726 shares changing hands. The stock had previously closed at $13.57.
Several equities analysts recently issued reports on the company. Chardan Capital reiterated a “buy” rating on shares of Regenxbio in a report on Monday. Zacks Investment Research upgraded Regenxbio from a “hold” rating to a “buy” rating and set a $8.75 price target on the stock in a report on Wednesday, July 6th. Finally, Piper Jaffray Cos. reiterated a “buy” rating and issued a $33.00 price target on shares of Regenxbio in a report on Tuesday, July 5th. One research analyst has rated the stock with a sell rating and four have issued a buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $26.75.
The stock has a 50-day moving average price of $9.33 and a 200 day moving average price of $10.92. The company’s market cap is $341.40 million.
Regenxbio (NASDAQ:RGNX) last released its earnings results on Tuesday, August 9th. The company reported ($0.55) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.53) by $0.02. On average, equities analysts expect that Regenxbio Inc. will post ($2.37) EPS for the current year.
An institutional investor recently raised its position in Regenxbio stock. RS Investment Management Co. LLC increased its position in shares of Regenxbio Inc. (NASDAQ:RGNX) by 11.3% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 746,592 shares of the company’s stock after buying an additional 75,810 shares during the period. RS Investment Management Co. LLC owned approximately 2.84% of Regenxbio worth $12,393,000 at the end of the most recent quarter.
REGENXBIO Inc is a biotechnology company. The Company is focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy. Its AAV gene delivery platform (its NAV Technology Platform) consists of rights to over 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10 (NAV Vectors).
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.